Search 

Shenzhen EFUNG Investment Management Enterprise L. P. is one of China's earliest institutions investing in professional biomedical industries. Our strong research team and great investment returns made us won 'The Most Pioneering VC Institution” 'The Most Dynamic Pharmaceutical VC Institution in China' and 'The Top Ten VC Institutions in Shenzhen'. Over a decade of years, we have been focusing on the medical and health industry, especially the VC and PE investment business of novel drugs and high-end medical devices. The mission of EFUNG is to drive the industrialization of medical researches by capital and to gain rich returns to investors. EFUNG has deeply screened and invested in more than 20 domestic and international premium enterprises, such as Chipscreen Biosciences, Frontier Biotechnologies, Ascentage Pharma, Lifotronic, Aridis Pharmaceuticals, and Centrexion. We have taken many years in the business and raised the core concept of 'taking entrepreneurs as the center and value creators as the basis'.

Private equity investment institutions in the secondary market, focusing on pharmaceutical consumption and other industries

Fosunpharma is a leading healthcare group in China. It has built a strong root domestically and developed a global operation strategy. With pharmaceutical manufacturing and R&D being core business segment, together with strong presences in medical devices and diagnostics, healthcare services, pharmaceutical distribution and retail.

Corporate Venture Capital function for PTT Global Chemical, the biggest polyolefin manufacturer in Southeast Asia.

Guoqian Medical Technology (Suzhou) Co., Ltd. was registered and established in Suzhou High-tech Zone in 2017.

Guoqian Medical has two business platforms: Guoqian Venture Capital and Guoqian Medical Technology Innovation Research Institute.

Guoqian Venture Capital is a professional and market-oriented venture capital institution that focuses on equity investment in early innovation and entrepreneurship projects in the fields of medical devices, in vitro diagnostic reagents and biotechnology. Focusing on high-end scientific and technological talents with Chinese major talent engineering experts as the core, they seek high-quality investment targets during the transformation of scientific and technological achievements, the introduction of technological projects, the evaluation of innovative and entrepreneurial projects, and the landing of innovative and entrepreneurial projects.

Guoqian Medical Technology Innovation Research Institute is committed to cultivating cutting-edge technologies and projects in the domestic medical device industry, and providing it with multi-faceted technologies, policies, talents, industrialization and markets through direct investment, entrepreneurial services, and scientific and technological achievement transformation services. Integration of services and resources to create an innovative platform for national technological innovation and industrial integration and empowerment. At the same time, it has also become an enabling platform for post-investment enterprises of Guoqian Fund. By creating industrial clusters and industrial ecology, it will provide post-investment management, post-investment services, and post-investment empowerment to post-investment enterprises.

Based on the business philosophy of “achieving the dreams of others”, Guoqian Medical uses market-oriented and specialized equity investment funds to create industrial agglomeration and industrial ecology; it empowers post-investment enterprises by creating industrial agglomeration and industrial ecology. The two platforms complement each other, and strive to build a medical device industry cluster and ecosystem in Suzhou High-tech Zone in 10 years, becoming one of the main promoters of the domestic medical device industry.

· About Us
Chairman，Mr. Rongguang WU is also the founder of Hongxing Erke , which is one of the most famous sports brands in China. We focus on investing in innovative biotech companies and healthcare funds worldwide. We have an expert team and also seek license-in opportunity of innovative drugs to develop and commercialize in China.

· Investment Cases

Previously, we've invested over 100 million dollars, more than 10 projects worldwide, including VIR Biotechnology, Beijing Genomics institution, GMAX Bio and two Top 10 biomedical funds in America, etc..

· Investment Preference

We don’t have clear limits on the investment scale and the proportion of shares, usually $5 million to $20 million of a single investment. Companies in initial stage to growth stage are all in our consideration. We can lead, co-lead, or join a round that others are leading.

Website：www.hongxingerke.com

PE/VC firm

Private Equity investment platform of ICBC.

ICBC Asia investment is a wholly-owned holding equity investment platform of industrial and commercial bank of China (ICBC). Managing over 44 billion yuan unlist equity investment. Direct investment over 172 projects, indirect investment in over 2400 companies.

Strategic investor